US Bancorp DE Cuts Holdings in Elevance Health, Inc. $ELV

Key Points

• US Bancorp DE trimmed holdings in Elevance Health by 11.4% in Q4, selling 6,624 shares and leaving it with 51,363 shares valued at about $18.0 million.
• Elevance beat expectations for the quarter — reporting $12.58 EPS vs. a $10.74 consensus and revenue of $49.49 billion vs. a $48.21 billion estimate.
• Dividend announced: a quarterly payment of $1.72 per share (annualized $6.88), with an ex-dividend date of June 10 and payment on June 25, implying a yield of about 1.8%.

US Bancorp DE trimmed its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,363 shares of the company's stock after selling 6,624 shares during the quarter. US Bancorp DE's holdings in Elevance Health were worth $18,005,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ELV. Simplicity Wealth LLC boosted its stake in Elevance Health by 20.0% in the fourth quarter. Simplicity Wealth LLC now owns 1,220 shares of the company's stock valued at $428,000 after acquiring an additional 203 shares in the last quarter. Joel Isaacson & Co. LLC boosted its stake in Elevance Health by 45.1% in the fourth quarter. Joel Isaacson & Co. LLC now owns 2,561 shares of the company's stock valued at $898,000 after acquiring an additional 796 shares in the last quarter. Pekin Hardy Strauss Inc. boosted its stake in Elevance Health by 448.0% in the fourth quarter. Pekin Hardy Strauss Inc. now owns 9,618 shares of the company's stock valued at $3,372,000 after acquiring an additional 7,863 shares in the last quarter. Keybank National Association OH boosted its stake in Elevance Health by 1.5% in the fourth quarter. Keybank National Association OH now owns 9,104 shares of the company's stock valued at $3,191,000 after acquiring an additional 132 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in Elevance Health in the fourth quarter valued at approximately $105,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Trading Down 1.0%

NYSE:ELV opened at $372.78 on Friday. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $424.24. The firm has a fifty day simple moving average of $310.69 and a 200-day simple moving average of $331.90. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $80.95 billion, a P/E ratio of 15.86, a PEG ratio of 2.14 and a beta of 0.49.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same period in the previous year, the firm posted $11.97 earnings per share. The business's revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts anticipate that Elevance Health, Inc. will post 26.79 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health's payout ratio is presently 29.26%.

Analyst Ratings Changes

Several brokerages have weighed in on ELV. Truist Financial lowered their target price on shares of Elevance Health from $390.00 to $375.00 and set a "buy" rating for the company in a research note on Monday, April 13th. Wall Street Zen downgraded shares of Elevance Health from a "buy" rating to a "hold" rating in a research note on Sunday, February 8th. Mizuho lowered their target price on shares of Elevance Health from $413.00 to $350.00 and set an "outperform" rating for the company in a research note on Wednesday, March 11th. Royal Bank Of Canada downgraded shares of Elevance Health from an "outperform" rating to a "sector perform" rating and set a $358.00 target price for the company. in a research note on Tuesday, February 3rd. Finally, Jefferies Financial Group lowered their target price on shares of Elevance Health from $395.00 to $391.00 and set a "buy" rating for the company in a research note on Monday, April 20th. Thirteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $384.58.

Elevance Health Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.